Syndax Pharmaceuticals Inc.
400 Totten Pond Road
Suite 110
Waltham
Massachusetts
02451
United States
Tel: 781-419-1400
Fax: 781-419-1420
Website: http://www.syndax.com/
Email: info@syndax.com
180 articles with Syndax Pharmaceuticals Inc.
-
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
3/7/2019
Next interim OS assessment for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19
-
Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019
2/28/2019
Syndax Pharmaceuticals, Inc. announced that it will release its fourth quarter 2018 financial results on Thursday, March 7, after the close of the U.S. financial markets.
-
Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019
2/27/2019
Syndax Pharmaceuticals, Inc. announced two oral presentations at the upcoming American Association for Cancer Research Annual Meeting being held March 29 - April 3, 2019 in Atlanta, Georgia.
-
Syndax Highlights 2019 Clinical and Corporate Outlook
1/7/2019
Data from ENCORE I/O combination program in melanoma and ovarian cancer expected in 1Q19, TNBC in 2Q19
-
Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting
12/3/2018
Preclinical data provide further support for the clinical application of Company's Menin-MLL program in acute leukemias
-
Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update
11/5/2018
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2018.
-
Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting
11/1/2018
Syndax Pharmaceuticals, Inc. today announced that the Company’s Menin-MLLr program will be featured during two presentations at the 60th American Society of Hematology (ASH) Annual Meeting being held December 1-4, 2018 in San Diego, California.
-
Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting
11/1/2018
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company's Menin-MLLr program will be featured during two presentations at the 60th American Society of Hematology (ASH) Annual Meeting
-
Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018
10/29/2018
Syndax Pharmaceuticals, Inc. announced today that it will release its third quarter 2018 financial results on Monday, November 5, after the close of the U.S. financial markets.
-
Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer
10/25/2018
Enrollment completed in E2112; PFS not statistically significant; trial continues as planned having passed 3rd interim analysis for OS with additional planned OS analyses every 6 months
-
Syndax to Present at the 2018 Cantor Global Healthcare Conference
9/26/2018
2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 9:10 a.m. ET at the InterContinental New York Barclay Hotel.
-
Twentyeight-Seven Therapeutics (28-7), announced it had completed a $65 million Series A financing. It was co-led by founding investor MPM Capital and Novartis Venture Fund. Joining them were Johnson & Johnson Innovation – JJDC, Vertex Ventures, Longwood Fund, and Astellas Venture Management.
-
Syndax Announces Participation at Three Upcoming September 2018 Investor Conferences
8/28/2018
Syndax Pharmaceuticals, Inc. today announced that members of the management team will participate in three upcoming investor conferences.
-
Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update
8/7/2018
Syndax Pharmaceuticals Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2018. In addition, the Company provided a clinical and business update. As of June 30, 2018, Syndax had $98.4 million in cash, cash equivalents and short-term investments.
-
It's been a busy week for Nektar Therapeutics with the announcement of an NDA submission to the FDA for NKTR-181 and a non-exclusive, clinical collaboration deal with Syndax Pharmaceuticals.
-
Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
5/30/2018
Syndax Pharmaceuticals, Inc. announced that members of the management team will participate in two upcoming investor conferences.
-
Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
5/30/2018
Syndax Pharmaceuticals, Inc. and Nektar Therapeutics announced a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar's NKTR-214.
-
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
-
Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update
5/10/2018
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2018. In addition, the Company provided a clinical and business update. As of March 31, 2018, Syndax had $113.2 million in cash, cash equivalents and short-term investments.
-
Syndax to Announce First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 8, 2018
5/1/2018
Syndax Pharmaceuticals, Inc. will release its first quarter 2018 financial results on Tuesday, May 8, 2018, after the close of the U.S. financial markets.